Epstein-Barr virus latent membrane protein 2 peptide–HLA complex (EBV LMP2-HLA complex)

The Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide–HLA complex is a critical immunological target for treating EBV-associated malignancies. LMP2 is a viral protein expressed during the latency II and III phases of the EBV life cycle, which are characteristic of diseases such as nasopharyngeal carcinoma and Hodgkin lymphoma (Source: PubMed, PMID: 15141015). These complexes consist of short peptide fragments derived from the LMP2 protein presented on the cell surface by Human Leukocyte Antigen (HLA) molecules, most commonly HLA-A*02:01 or HLA-A*11:01 (Source: PubMed, PMID: 22438243). Because LMP2 is not expressed in healthy non-infected tissues, these complexes serve as highly specific neoantigen-like targets for cytotoxic T lymphocytes (CTLs). Therapeutic strategies targeting these complexes include adoptive T-cell therapies, such as EBV-specific T cells (EBVSTs) and TCR-engineered T cells, as well as therapeutic vaccines designed to boost the endogenous immune response (Source: ClinicalTrials.gov). By engaging these complexes, drugs and cellular therapies can selectively eliminate tumor cells while sparing healthy tissue. However, challenges such as HLA downregulation and the immunosuppressive tumor microenvironment remain significant hurdles in achieving durable clinical responses (Source: PubMed, PMID: 30635945).

Other names

LMP2-MHC complexEBV LMP2 peptide-MHCLatent membrane protein 2-HLA complexLMP2A-HLA complexLMP2B-HLA complex

Recognition by T-cell receptors (TCRs) on cytotoxic T lymphocytes (CTLs), leading to the targeted lysis of EBV-infected or transformed cells expressing the LMP2 protein.